Lexicon Pharmaceuticals, Inc.
LXRX
$1.88
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 69.64M | 49.80M | 70.86M | 58.43M | 31.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.64M | 49.80M | 70.86M | 58.43M | 31.21M |
| Cost of Revenue | -10.03M | -7.56M | -15.86M | -8.77M | -8.58M |
| Gross Profit | 79.68M | 57.37M | 86.72M | 67.20M | 39.79M |
| SG&A Expenses | 34.94M | 37.32M | 60.82M | 92.81M | 122.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.87M | 98.71M | 136.63M | 175.71M | 207.58M |
| Operating Income | -24.23M | -48.91M | -65.77M | -117.27M | -176.36M |
| Income Before Tax | -26.09M | -50.34M | -68.58M | -120.62M | -177.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.09 | -50.34 | -68.58 | -120.62 | -177.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.09M | -50.34M | -68.58M | -120.62M | -177.30M |
| EBIT | -24.23M | -48.91M | -65.77M | -117.27M | -176.36M |
| EBITDA | -23.67M | -48.29M | -65.14M | -116.67M | -175.80M |
| EPS Basic | -0.07 | -0.14 | -0.19 | -0.33 | -0.51 |
| Normalized Basic EPS | -0.04 | -0.09 | -0.12 | -0.21 | -0.32 |
| EPS Diluted | -0.07 | -0.14 | -0.19 | -0.33 | -0.51 |
| Normalized Diluted EPS | -0.04 | -0.09 | -0.12 | -0.21 | -0.32 |
| Average Basic Shares Outstanding | 1.49B | 1.45B | 1.45B | 1.45B | 1.40B |
| Average Diluted Shares Outstanding | 1.49B | 1.45B | 1.45B | 1.45B | 1.40B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |